As COVID-19 spread across the globe last spring, investors rushed to precious metals as a financial safe haven. Gold rose to over $2,000 by early August, up more than 30% from the start of the year. Silver surged more than 50% over the same period, reflecting the common correlation among precious metals during times of financial uncertainty or volatility.
Providing financial protection is not the only role that precious metals are playing in the fight against COVID-19. The metals also have broad applications in the medical field, well beyond the dental uses most people associate with them.
Researchers have developed drugs and tests that use silver to detect and protect against the virus. Serological assays, a type of blood test, employ silver and gold nanoparticles1 to quickly determine if antigens exist in a patient’s bloodstream.2 These are critical in determining if the person is infectious and to ensure that donated plasma used to treat ill patients is safe.3
Figure 1. COVID-19 Serology Tests (Antibody Tests)
Beyond silver’s diagnostic and therapeutic uses in the fight against COVID-19, there are also trace amounts of silver in the fabric of some masks.4 While not anti-viral, silver does protect against other bacteria and eliminates odors, which helps when wearing the masks for extended periods of time.
The fight against COVID-19 highlights a trend: growing demand for precious metals in healthcare. This has particular relevance now, but also into the near future as the population continues to age. National health spending in the U.S. is expected to rise to 19.4% of GDP (gross domestic product) by 2027, or $6 trillion a year, representing a generational shift in spending.5 Precious metals, because of their unique physical attributes, are expected to play a role in this shift.
Treatments for certain cancers employ gold and platinum. This role has the potential to grow, accelerated by recent breakthroughs.
Since its natural properties slow cells — both healthy and cancerous ones — from dividing, platinum (Pt) has long been used in chemotherapy treatments, including in drugs known as cisplatin and carboplatin.6 A downside to these platinum-based drugs is their non-specificity, which creates some of the adverse side-effects in chemotherapy, like hair loss.
Figure 2. Chemical Structures of Cisplatin and Transplatin
Gold nanoparticles have become a focus of a new type of more targeted treatment. Researchers are testing therapies that use gold-silica nanoshells to target cancer cells, preventing the diseased areas from spreading.7 Similar to the platinum treatments, it essentially suffocates the diseased cells, but the gold nanoparticles are more effective in attacking the unwanted cells. This treatment has shown particular promise in prostate cancers, a disease that impacts about 11% of men.8
Gold nanoparticles (tiny spheres made of gold atoms with a diameter of only a few billionths of a meter) have also shown potential in the testing and treating of HIV/AIDS. In a study, researchers were able to detect the HIV virus, even in situations where the virus had little development. This brings hope of earlier detection. In an early study of monkeys with an HIV-like virus, gold nanoparticles reduced the number of infected cells. Though still very early days for this research, it provides some promising potential.9
Gold has anti-inflammatory properties that help reduce joint inflammation and pain, and gold preparations were among the original treatments for rheumatoid arthritis (RA). Gold is also used in rapid tests for malaria, allowing doctors to test the disease within 20 minutes. This has value, particularly in parts of the world where there they lack access to labs.
Platinum and palladium have similar biological properties. While platinum is typically selected for many uses, palladium can stand in platinum’s stead for biological purposes.
Since precious metals are inert, they react with other chemicals in few naturally occurring environments. They are also electrically conductive, opening applications where the body or organs are stimulated directly. And they are strong, so they do not break easily. This has encouraged the broad use of platinum in catheters. Electrophysiology catheters, for example, use electrodes to measure cardiac muscle activity.10 The platinum electrodes make the device possible.
Figure 3. Gold Nanoparticles Support New Drug Development and Drug Delivery Systems
Germs do not spread on a silver surface, due to its anti-microbial properties. This makes it an ideal component of many of the devices and tools one sees in a hospital. In fact, silver is much more useful in medical devices than in medicines because of its toxicity – too much silver in the body can cause Argyria, a blue or grey hue in the skin. But in the medical technology field, it has a place because of this germ-protective property. Staphylococcus aureus, a dangerous and highly infectious bacterium, spreads quickly in hospitals. To limit the spread, hospitals often use equipment lined with silver, from surgical tools to stethoscopes to even the furniture.11 Silver is also often incorporated in breathing tubes and catheters to protect against infections.
Platinum is also broadly used in medical devices, including stents and pacemakers, in addition to catheters. Platinum reduces the likelihood that the body will reject the devices. It also appears in X-rays, allowing healthcare workers to track the progress of the operation.
Platinum plays a critical role in neuromodulation devices, which help treat Parkinson's patients' neurological conditions by sending electric signals to the central nervous system. In these “brain pacemakers,” there is platinum in the electrodes and within some of the device’s components.12
Figure 4. Platinum (Pt) is a Critical Components in Implantable Cardioverter Defibrillator
Source: Johnson Matthey.
The healthcare sector represents approximately 3-5% of the overall precious metals market. However, as our society ages and the need for healthcare applications increases, the use and demand for precious metals in medicine will continue to expand. This often overlooked contribution of precious metals to fighting disease speaks to the broader value of these metals and their critical multi-varied roles.
Past performance is no guarantee of future results. You cannot invest directly in an index. Investments, commentary and statements are unique and may not be reflective of investments and commentary in other strategies managed by Sprott Asset Management USA, Inc., Sprott Asset Management LP, Sprott Inc., or any other Sprott entity or affiliate. Opinions expressed in this commentary are those of the presenter and may vary widely from opinions of other Sprott affiliated Portfolio Managers or investment professionals.
This content may not be reproduced in any form, or referred to in any other publication, without acknowledgment that it was produced by Sprott Asset Management LP and a reference to sprott.com. The opinions, estimates and projections (“information”) contained within this content are solely those of Sprott Asset Management LP (“SAM LP”) and are subject to change without notice. SAM LP makes every effort to ensure that the information has been derived from sources believed to be reliable and accurate. However, SAM LP assumes no responsibility for any losses or damages, whether direct or indirect, which arise out of the use of this information. SAM LP is not under any obligation to update or keep current the information contained herein. The information should not be regarded by recipients as a substitute for the exercise of their own judgment. Please contact your own personal advisor on your particular circumstances. Views expressed regarding a particular company, security, industry or market sector should not be considered an indication of trading intent of any investment funds managed by Sprott Asset Management LP. These views are not to be considered as investment advice nor should they be considered a recommendation to buy or sell. SAM LP and/or its affiliates may collectively beneficially own/control 1% or more of any class of the equity securities of the issuers mentioned in this report. SAM LP and/or its affiliates may hold short position in any class of the equity securities of the issuers mentioned in this report. During the preceding 12 months, SAM LP and/or its affiliates may have received remuneration other than normal course investment advisory or trade execution services from the issuers mentioned in this report.
SAM LP is the investment manager to the Sprott Physical Bullion Trusts (the “Trusts”). Important information about the Trusts, including the investment objectives and strategies, purchase options, applicable management fees, and expenses, is contained in the prospectus. Please read the document carefully before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. This communication does not constitute an offer to sell or solicitation to purchase securities of the Trusts.
The risks associated with investing in a Trust depend on the securities and assets in which the Trust invests, based upon the Trust’s particular objectives. There is no assurance that any Trust will achieve its investment objective, and its net asset value, yield and investment return will fluctuate from time to time with market conditions. There is no guarantee that the full amount of your original investment in a Trust will be returned to you. The Trusts are not insured by the Canada Deposit Insurance Corporation or any other government deposit insurer. Please read a Trust’s prospectus before investing.
The information contained herein does not constitute an offer or solicitation to anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation. Prospective investors who are not resident in Canada or the United States should contact their financial advisor to determine whether securities of the Funds may be lawfully sold in their jurisdiction.
The information provided is general in nature and is provided with the understanding that it may not be relied upon as, nor considered to be, the rendering or tax, legal, accounting or professional advice. Readers should consult with their own accountants and/or lawyers for advice on the specific circumstances before taking any action.
© 2021 Sprott Inc. All rights reserved.
You are now leaving Sprott.com and entering a linked website. Sprott has partnered with ALPS in offering Sprott ETFs. For fact sheets, marketing materials, prospectuses, performance, expense information and other details about the ETFs, you will be directed to the ALPS/Sprott website at SprottETFs.com.Continue to Sprott Exchange Traded Funds
You are now leaving Sprott.com and entering a linked website. Sprott Asset Management is a sub-advisor for several mutual funds on behalf of Ninepoint Partners. For details on these funds, you will be directed to the Ninepoint Partners website at ninepoint.com.Continue to Ninepoint Partners
You are now leaving sprott.com and linking to a third-party website. Sprott assumes no liability for the content of this linked site and the material it presents, including without limitation, the accuracy, subject matter, quality or timeliness of the content. The fact that this link has been provided does not constitute an endorsement, authorization, sponsorship by or affiliation with Sprott with respect to the linked site or the material.Continue